Dr. Atkins on Sequencing of Immunotherapy Combination Regimens

Michael B. Atkins, MD
Published: Wednesday, Aug 02, 2017



Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses sequencing of immunotherapy combination regimens for patients with renal cell carcinoma (RCC).

According to Atkins, an issue that physicians are facing is whether to give first-line and second-line treatments together versus giving them in sequence.

The immunotherapies are all being tested in the adjuvant setting with data to be released in the coming years. This will further complicate the sequencing of agents for patients with RCC, states Atkins.
 


Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses sequencing of immunotherapy combination regimens for patients with renal cell carcinoma (RCC).

According to Atkins, an issue that physicians are facing is whether to give first-line and second-line treatments together versus giving them in sequence.

The immunotherapies are all being tested in the adjuvant setting with data to be released in the coming years. This will further complicate the sequencing of agents for patients with RCC, states Atkins.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x